Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Crypto ETNs will soon be available to UK retail investors, FCA says

(Sharecast News) - The UK financial regulator announced on Friday that it is planning to allow retail investors to access crypto exchange traded notes (cETNs), lifting a ban on market that has been in place for more than four years. In January 2021, the Financial Conduct Authority banned the sale, marketing and distribution of derivatives and ETNs that reference unregulated transferable cryptoassets to retail clients.

After announcing in March 2024 that it would allow investment exchanges to create a UK-listed market segment for cETNs for professional investors, the FCA has been consulting on proposals to lift the ban on retail access for the past two months.

The development comes as the regulator continues to figure out a regulatory framework for cryptoassets.

"Since we restricted retail access to cETNs, the market has evolved, and products have become more mainstream and better understood," said David Geale, executive director of payments and digital finance at the FCA.

"In light of this, we're providing consumers with more choice, while ensuring there are protections in place. This should mean people get the information they need to assess whether the level of risk is right for them."

The FCA said that, as long as cETNs are traded on an FCA-approved investment exchange based in the UK, retail consumers will be able to access them.

Investment exchanges must make sure they meet regulatory standards, including ensuring that consumers aren't offered "inappropriate incentives to invest".

A ban on cryptoasset derivatives, however, will remain in place, the FCA said on Friday.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.